Search Results

You are looking at 1 - 10 of 210 items for :

  • survival analysis x
Clear All
Open access

Jes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, Per Løgstrup Poulsen, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Sten Schytte, Stefano Christian Londero, Henrik Baymler Pedersen, Christoffer Holst Hahn, Jens Bentzen, Sören Möller, Mette Gaustadnes, Maria Rossing, Finn Cilius Nielsen, Kim Brixen, Christian Godballe and Danish Thyroid Cancer Group (DATHYRCA)

until death, emigration or last follow-up (January 1, 2018), whichever came first. For calculation of overall and disease-specific survival, all deaths and deaths due to MTC were considered as an event, respectively. Statistical analysis

Open access

Hanbaro Kim, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Shadi Alshammary and Song Cheol Kim

mean tumor size of NF-PNETs over time. When we analyzed the tumor grade over time, the proportion of grade G3 tumors was lowest (6.6%) in the late period. In the survival analysis, we found that DSS and DFS according to each time period tended to

Open access

Ashley K Clift, Omar Faiz, Robert Goldin, John Martin, Harpreet Wasan, Marc-Olaf Liedke, Erik Schloericke, Anna Malczewska, Guido Rindi, Mark Kidd, Irvin M Modlin and Andrea Frilling

IIIA, 19 (27.1%) were stage IIIB and 44 (62.9%) were stage IV at the time of initial presentation. On Kaplan–Meier analysis, the median estimated survival for patients with G1 tumours was 156 months. For G2 tumours, no median estimated survival could

Open access

Wentao Zhou, Tiantao Kuang, Xu Han, Wenqi Chen, Xuefeng Xu, Wenhui Lou and Dansong Wang

cut-off values of LMR for G1, G2 and G3 were 5.0, 4.4 and 3.5, respectively (Supplementary Fig. 4). Survival analysis manifested that LMR >4.4 was associated with favorable prognosis in G2 patients ( P  = 0.020), but no statistical difference was

Open access

Lauren E Henke, John D Pfeifer, Thomas J Baranski, Todd DeWees and Perry W Grigsby

analysis of 542 patients with established BRAF status, presence of the BRAF mutation did not independently predict C-PTC histology. Patient outcomes For the entire cohort, overall survival was 92.5 and 90.3% at 10 and 15 years, respectively. RFS

Open access

June Young Choi, Jin Wook Yi, Jun Hyup Lee, Ra-Yeong Song, Hyeongwon Yu, Hyungju Kwon, Young Jun Chai, Su-jin Kim and Kyu Eun Lee

–Meier estimator with log-rank test was used for survival analysis. Differentially expressed genes (DEG) and gene ontology (GO) tests between two VDR groups were performed using ‘EdgeR’ package, which is one of the bioinformatics tools in Bioconductor ( https

Open access

B C M Hermans, J L Derks, H J M Groen, J A Stigt, R J van Suylen, L M Hillen, E C van den Broek, E J M Speel and A-M C Dingemans

). Median overall survival (OS) was evaluated by Kaplan–Meier analysis and differences in survival between low and high Ki-67 PI (arbitrary threshold ≤40 vs >40%) were tested for significance with log-rank test. P  < 0.05 was considered significant. The

Open access

Yang Lv, Ning Pu, Wei-lin Mao, Wen-qi Chen, Huan-yu Wang, Xu Han, Yuan Ji, Lei Zhang, Da-yong Jin, Wen-Hui Lou and Xue-feng Xu

Characteristics of patients in SEER cohort: univariate and multivariate analysis. Characteristics Patients Overall Survival Univariate analysis Multivariate analysis Multivariate HR 95% Confidence interval (CI) Total 1028

Open access

Ishita Gupta, Allal Ouhtit, Adil Al-Ajmi, Syed Gauhar A Rizvi, Hamad Al-Riyami, Marwa Al-Riyami and Yahya Tamimi

polymorphisms and breast cancer disease. Kaplan–Meier method was used for survival analysis and significant differences between gene expression and overall survival was compared using the log-rank test. Based on a previous study ( 6 ), breast cancer patients

Open access

Samira M Sadowski, Emanuel Christ, Benoit Bédat, Attila Kollár, Wolfram Karenovics, Aurel Perren, Frédéric Triponez and on behalf of the SwissNET registry

lung in Switzerland. The secondary aims included (i) the analysis of clinical and biomedical factors associated with surgical therapy and survival and (ii) the analysis of the current treatment strategies in Switzerland in relation to current guidelines